Tag: cerebroprotective drugs
Positive loberamisal data underscore potential role for multi-target neuroprotective agents in...
Stroke patients who intravenously received the novel neuroprotective medication loberamisal (NeuroDawn Pharmaceutical) on a daily basis—for 10 days and starting within 48 hours of...
“The race is on”: enthusiasm over neuroprotection endures despite historic failures
“The race is on—don’t miss the bus!”, were the words of David Liebeskind (University of California Los Angeles Health, Los Angeles, USA) as he...
AptaTargets announces publication of APRIL trial data in JAMA Neurology
As per a press release from AptaTargets, JAMA Neurology has published positive results from APRIL—a Phase 1b/2a clinical trial evaluating the safety and efficacy...
Astrocyte to initiate extended infusion Phase 1b study of cerebroprotective drug
Astrocyte Pharmaceuticals has announced the initiation of a Phase 1b study of its lead cerebroprotective candidate, AST-004, as an extended infusion in healthy volunteers....
